Farletuzumab, a humanized monoclonal antibody against folate receptor α, in epithelial ovarian cancer: A phase I study
Folate Receptor 1
Neoplasms, Glandular and Epithelial
In this phase I study, farletuzumab administered as an i.v. infusion at doses of 12.5 to 400 mg/m(2) was generally safe and well tolerated in the management of heavily pretreated patients with epithelial ovarian cancer.